TAMPA, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE:BTTR) ("Better Choice" or "the Company"), a pet health and wellness company, today announced that its Board of Directors has formed a special committee consisting of Lionel Conacher, John Word III and Michael Young. The committee's mandate will be to evaluate all and any M&A and asset monetization opportunities, including joint ventures, acquisitions, dispositions, and may re-engage certain candidates previously expressing an in ...

文章核心观点 - 公司是一家临床阶段的制药公司,专注于开发用于治疗帕金森病及相关疾病的蛋白激酶抑制剂治疗药物 [1][3] - 公司将于2024年8月14日发布2024年第二季度财务业绩,并于次日召开电话会议和网络直播,提供公司更新信息并回顾财务业绩 [1][2] 公司概况 - 公司总部位于佐治亚州亚特兰大,在马萨诸塞州列克星敦也设有办公室 [3] - 公司的多治疗管线主要针对神经退行性疾病,其领先项目risvodetinib是一种Abelson酪氨酸激酶(c-Abl)抑制剂,针对治疗大脑内外的帕金森病及其他由Abelson酪氨酸激酶引起的疾病 [3] - 公司的多治疗管线还在研究与帕金森病相关的大脑和胃肠道疾病、与帕金森病相关的孤儿适应症(如多系统萎缩)以及激酶抑制剂的给药技术,如IkT-001Pro(imatinib间充毒的前药) [3] - 公司的RAMP™化学合成项目已经发现了几个可能应用于大脑认知和运动功能疾病的risvodetinib后续化合物 [3]

THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Posters will be displayed in the poster area of Exhibition Hall B from Friday, August 9 through Sunday, August 12. All three presentations will occur on ...

Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global ...

BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinicalstage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. ("Aeries" or "the Company") (NASDAQ:AERT), a global professional services and consulting partner, is confirmed to present at the 2024 Annual Gateway Conference, which is being held September 4-5, at the Four Seasons Hotel in San Francisco, CA. Aeries' management team is scheduled to present on Thursday, September 5 at 8:30 a.m. Pacific Time (PT). In addition to the presentation, Aeries executives will be available for one-on-one meetings th ...

文章核心观点 - 研究发现细胞外ASC在AA淀粉样变性的发病机理和程度中起关键作用,与IL-1β无关 [1][2][3] - 细胞外ASC与肝脏在炎症期间释放的血清淀粉A(SAA)相互作用,形成支架加速SAA聚集成淀粉样纤维,沉积在组织和器官中 [1][4] - AA淀粉样变性发生于类风湿性关节炎、克罗恩病和炎性肠病等多种慢性炎症性疾病 [1] - 公司正在开发一种创新的炎症体ASC抑制剂IC 100,可抑制多种炎症体内外的ASC和ASC颗粒,从而减弱有害炎症及其持续和蔓延 [1][6] 公司概况 - 公司是一家处于临床阶段的专业生物制药公司,专注于开发治疗炎症和肾脏疾病的首创药物 [7][8] - 公司在快速崛起的炎症体领域拥有一款高度差异化的单克隆抗体IC 100,在肾脏疾病领域也有一款处于2期临床的药物VAR 200 [8] - IC 100的首个适应症是肥胖及其代谢并发症,VAR 200的首个适应症是局灶节段性肾小球硬化症(FSGS) [8] - 公司的两大治疗领域都有"产品内管线"的潜力,可拓展至多个适应症,总可及市场规模超过1000亿美元 [8]

ATHENS, Greece, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OceanPal Inc. (NASDAQ:OP) (the "Company"), a global shipping company specializing in the ownership of vessels, today reported time charter revenues of $6.7 million, a net loss of $8.2 million and net loss attributed to common stockholders of $8.6 million for the second quarter of 2024. This compares to time charter revenues of $5.4 million, a net income of $1.3 million and net income attributed to common stockholders of $483 thousand for the second quarter o ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief F ...

ROSH-HA`AYIN, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Kornit Digital Ltd. ("Kornit" or the "Company") (NASDAQ:KRNT), a worldwide market leader in sustainable, on-demand, digital fashionX and textile production technologies, today announced that the Company will host an Investor Event on Tuesday, September 10th, 2024 at the Westgate in Las Vegas, NV, in conjunction with its participation at the Printing United trade show. During the Investor Event, the Company will provide insights into its recent business ...